Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

13.64 +0.14 (+1.07%)
Streaming Delayed Price Updated: 11:19 AM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 83,934
Open 13.49
Bid (Size) 13.63 (1)
Ask (Size) 13.66 (1)
Prev. Close 13.50
Today's Range 13.44 - 13.67
52wk Range 7.300 - 17.28
Shares Outstanding 34,233,643
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
KalVista Posts 154% Expense Jump in Q1
Via The Motley Fool
KalVista Pharmaceuticals Inc (NASDAQ:KALV) Stock Rises 7.4% on Strong EKTERLY Launch Despite Q1 Earnings Miss
KalVista stock rises 7.4% on strong EKTERLY launch, despite Q1 revenue miss and wider EPS loss. Early HAE treatment adoption exceeds expectations. 
Via Chartmill

Performance

YTD
+54.0%
+54.0%
1 Month
+2.3%
+2.3%
3 Month
+12.4%
+12.4%
6 Month
+10.3%
+10.3%
1 Year
+26.7%
+26.7%

More News

Read More
KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For September 11, 2025
Via Benzinga
KalVista Pharma's Earnings: A Preview
Via Benzinga
KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
Via Benzinga
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
From Metagenomi, Inc.
Via GlobeNewswire
KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday
Via Benzinga
KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated
Via Stocktwits
KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease
Via Benzinga
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is KalVista Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, KalVista Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does KalVista Pharmaceuticals, Inc. - Common Stock trade on?
KalVista Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock is KALV on the Nasdaq Stock Market
What is the current price of KalVista Pharmaceuticals, Inc. - Common Stock?
The current price of KalVista Pharmaceuticals, Inc. - Common Stock is 13.64
When was KalVista Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of KalVista Pharmaceuticals, Inc. - Common Stock was at 09/17/25 11:19 AM ET
What is the market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock?
The market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock is 467.12M
How many shares of KalVista Pharmaceuticals, Inc. - Common Stock are outstanding?
KalVista Pharmaceuticals, Inc. - Common Stock has 467M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.